David Borges Biography and Net Worth

CAO of Omeros

David J. Borges joined Omeros in June 2020 and has served as our vice president, finance, chief accounting officer and treasurer since June 2024. Prior to joining Omeros, Mr Borges served as vice president, finance and administration, at Bulletproof 360, Inc., a health and wellness company, where he directed and managed all aspects of corporate finance, accounting, information technology, human resources, facilities, and legal from October 2014 until October 2019. From May 2009 to June 2014, Mr Borges served as chief financial officer and vice president of Advanced Refreshment LLC, a producer of private label bottled water and water-based beverages. From July 2001 to May 2009, Mr Borges served as finance and business integration director at Merck & Co., Inc. (“Merck”), a biopharmaceutical company, after Merck acquired Rosetta Inpharmatics, where Mr Borges had been serving as director of finance & administration/controller since 1998. Mr Borges is a certified public accountant and received his BS in Commerce in Accounting from Santa Clara University.

How old is David J. Borges?: Borges is currently 60 years old. There are 8 older executives and no younger executives at Omeros. The oldest executive at Omeros is Dr. George A. Gaitanaris M.D., Ph.D., Chief Scientific Officer & VP of Science, who is 67 years old. Learn More on David J. Borges' age.
How do I contact David J. Borges?: The corporate mailing address for Borges and other Omeros executives is 201 ELLIOT AVENUE WEST, SEATTLE WA, 98119. Omeros can also be reached via phone at (206) 676-5000 and via email at [email protected]. Learn More on David J. Borges' contact information.
Has David J. Borges been buying or selling shares of Omeros?: During the last ninety days, David J. Borges has sold $369,300.00 in Omeros stock. Most recently, David J. Borges sold 30,000 shares of the business's stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $12.31, for a transaction totalling $369,300.00. Learn More on David J. Borges' trading history.
Who are Omeros' active insiders?: Omeros' insider roster includes David Borges (CAO), Gregory Demopulos (CEO), Peter Demopulos (Director), and Michael Jacobsen (CAO). Learn More on Omeros' active insiders.
Are insiders buying or selling shares of Omeros?: During the last year, insiders at the biopharmaceutical company sold shares 1 times. They sold a total of 30,000 shares worth more than $369,300.00. The most recent insider tranaction occured on January, 13th when CAO David J Borges sold 30,000 shares worth more than $369,300.00. Insiders at Omeros own 12.9% of the company. Learn More about insider trades at Omeros.
Information on this page was last updated on 1/13/2026.

David J. Borges Insider Trading History at Omeros

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/13/2026	Sell	30,000	$12.31	$369,300.00

David J. Borges Buying and Selling Activity at Omeros

Omeros Company Overview

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Today's Range

Now: $11.69

$11.45

$12.14

50 Day Range

MA: $12.29

$8.75

$17.17

2 Week Range

Now: $11.69

$2.95

$17.65

Volume

790,665 shs

Average Volume

1,231,275 shs

Market Capitalization

$828.82 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.45